

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Evaluation

Equality impact assessment – Scoping

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

Acute myeloid leukaemia (AML) is more common in men and older adults.

The company have indicated that the licensed indication for histamine dihydrochloride with IL-2 will state ‘the efficacy of histamine dihydrochloride 0.5 mg/0.5 mL solution for injection has not been fully demonstrated in patients older than age 60.’
--

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|--|

NICE will appraise within the marketing authorisation and cannot make a recommendation outside the marketing authorisation, but will consider all evidence available
--

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No	

Approved by Associate Director (name): ...Lorna Dunning.....
Date:24/06/2025